Regulatory approval

Published by the Health Canada.

Health Canada approved trametinib in combination with dabrafenib for the adjuvant treatment of patients with BRAF V600E or V600K-mutant melanoma and lymph node involvement after complete resection.

This is written in the approval document as:

MEKINIST (trametinib), in combination with dabrafenib, is indicated for the adjuvant treatment of patients with melanoma with a BRAF V600 mutation and involvement of lymph nodes, following complete resection.

Citation

Novartis Pharmaceuticals Canada Inc. Mekinist (trametinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077955.PDF. Revised December 2024. Accessed June 2025.

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Type Biomarker(s) Cancer type Therapy(ies)